Data on differences in AUC, expected peak and trough
serum concentrations, and pharmacokinetic/pharmacodynamic parameters (e.g. AUC: proposed MIC breakpoint ratio)
with anticipated dosage regimens are helpful, if available. As
well as data on normal human subjects, data on target populations which might include children, the elderly and populations with special dosage requirements (e.g. in renal or hepatic failure) are desirable.